Eli Lilly scored a victory in the first U.S. trial over claims of withdrawal symptoms linked to its blockbuster antidepressant, Cymbalta, as a federal jury found the drugmaker was not responsible for side effects such as brain zaps and suicidal ideations in a patient who quit the med.
Markets reacted very poorly when Biogen recently cut its earnings forecast on "headwinds" slowing Tecfidera sales because doctors are concerned about reports tying it to the rare but sometimes fatal brain infection known as PML. Now that wind has picked up after a report in a leading medical journal predicted more cases of the disease and called for deeper studies of the risks.
Earlier this year, a U.S. judge dealt Eli Lilly a stinging blow after refusing to toss out lawsuits claiming that the company downplayed withdrawal symptoms linked to its blockbuster antidepressant, Cymbalta. Now Lilly is facing the first U.S. trials over the claims, a critical moment as it attempts to disentangle itself from a raft of litigation.
An analysis by AdverseEvents shows the new generation of obesity meds are holding their own, safety-wise. Still, postmarketing data flag some serious cardiovascular and neuropsychiatric side effects that are worth monitoring, the healthcare informatics firm says.
Biogen has confirmed another case of progressive multifocal leukoencephalopathy in a patient on its oral MS-fighter Tecfidera, though this one--unlike the last--was nonfatal.
The FDA already had a warning out about the cardiovascular safety of nonsteroidal anti-inflammatory drugs, or NSAIDs. But on Thursday, it strengthened that warning for both prescription and OTC meds.
Antidepressants have long been linked to an increased risk of birth defects, with companies fighting claims that the meds cause serious issues in newborns if women take the drugs during pregnancy. Now, a new study published in the British Medical Journal shows that only some of the drugs turn up risks of birth defects, dealing a spate of good news to companies making the products.
A new national poll shows that parents' views on vaccines became more favorable between 2014 and 2015, the same period that multiple outbreaks of measles and whooping cough unrolled around the country.
A team of Stanford University scientists think they have found a potential reason why GlaxoSmithKline's now-withdrawn flu shot Pandemrix was associated with a spike in narcolepsy cases.
Drugmakers are eager to jump on the rheumatoid arthritis (RA) bandwagon, concentrating on tried-and-true treatments to bring in sales or developing new therapies to stave off looming biosimilars competition. But the meds come with their own set of safety issues, as both TNF-alpha treatments and non-TNF alpha drugs continue to generate troubling side effect reports.